Skip to main navigation
Lineage Cell Therapeutics
  • Company
    • About Us
    • Leadership
    • Board of Directors
    • Careers
    • Contact
  • Pipeline
    • Overview
    • OpRegen® for Dry AMD
    • OPC1
    • VAC2
  • Technology
    • Lineage Platform
    • Manufacturing
  • Media
  • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Leadership
      • Board of Directors
      • Committee Composition
    • Analyst Coverage
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxy Information
      • 2018 AgeX and Form 10 Information Statement
      • 2019 Form 8937
    • E-mail Alerts
    • Contact IR
  • Menu
  • Investors

    Lineage is a clinical-stage biotechnology company developing novel cell therapies

Investors

NYSE AMERICAN: LCTX

Data Provided by Refinitiv. Minimum 15 minutes delayed.

 
VIEW STOCK QUOTE
Press Releases
June 02, 2022
Lineage Broadens Collaboration With Advanced BioMatrix for HyStem® Cell Drug Delivery Technology
May 12, 2022
Lineage Cell Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
May 05, 2022
Lineage Cell Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 12, 2022
VIEW PRESS RELEASES
Events & Presentations
H.C. Wainwright & Co. Global Investment Conference
May 24, 2022
First Quarter 2022 Financial Results Earnings Call
May 12, 2022 at 4:30 PM EDT
2022 Association for Research in Vision and Ophthalmology Annual Meeting
May 2, 2022
VIEW EVENTS & PRESENTATIONS
© Copyright - Lineage Cell Therapeutics, Inc.   |   Terms of Use & Privacy   |   contact@lineagecell.com
  • Facebook
  • Twitter
  • RSS Feed
  • Email Alerts
Scroll to top